By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
Eureka Therapeutics And Boehringer Ingelheim Announce A Collaboration To Identify Next Generation Antibodies For Cancer Treatment 5/22/2015 8:52:26 AM
Boehringer Ingelheim Release: New Data Show Benefit Of Tiotropium/Olodaterol Respimat From The Start Of COPD Maintenance Therapy1,2,3 5/20/2015 11:36:24 AM
Boehringer Ingelheim Release: New Data Analyses On Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared To Tiotropium And Olodaterol Alone 5/20/2015 11:05:32 AM
Boehringer Ingelheim Acquires Pharmaxis (PXS.AX)’ Phase 1 Anti-Inflammatory Drug Candidate 5/18/2015 11:08:03 AM
Boehringer Ingelheim Presents New Data And Analyses Reinforcing The Safety And Efficacy Of OFEV (nintedanib) Capsules 5/18/2015 6:46:15 AM
Pharmaxis (PXS.AX) Shares Catapult on $750 Million Liver Drug Sale to Boehringer Ingelheim 5/18/2015 6:09:16 AM
Boehringer Ingelheim Showcases Expanding Presence In Lung Cancer At ASCO With New Data Including Presentation Of Gilotrif (Afatinib) Overall Survival Results For Squamous Cell Carcinoma Of The Lung 5/14/2015 11:23:26 AM
Boehringer Ingelheim Release: First Patient Enrolled In Dabigatran Study Comparing Anticoagulation Strategies During AF Ablation 5/14/2015 10:53:47 AM
Boehringer Ingelheim Release: First Patient Enrolled In Dabigatran Study Comparing Anticoagulation Strategies During AF Ablation 5/13/2015 1:32:40 PM
Boehringer Ingelheim To Present 29 Abstracts At The Annual American Thoracic Society International Conference 5/5/2015 10:28:05 AM
12345678910...
//-->